The group's principle activities include discovering, development and commercialization of innovative biomarkers for early and accurate detection of prostate, colon and various forms of cancer with lung, breast, liver, pancreatic and stomach. The group's product lines include ProstaMark(R) EPCA-2 serum assay, ProstaMark(R) EPCA tissue assay, and ColoMark CCSA-4 serum assay. The group operates from United States.
